Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Published 13/10/2023, 15:26
Updated 13/10/2023, 16:40
© Reuters.  Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Benzinga - by Chris Katje, Benzinga Staff Writer.

Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance to uncover new information.

Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks each week that are just under the surface and warrant attention.

The index layers editorial commentary to help make sense of why these stocks should be of interest and whether investors and casual readers should watch them. Here is a look at the Benzinga Stock Whisper Index for the week of Oct. 13, 2023:

Related Link: Israel Could Form Emergency Government, Defense Stocks, Israel ETFs In Focus During Conflict

  • Edesa Biotech Inc (NASDAQ: EDSA): Shares saw increased attention and high volatility over the week after the company announced a reverse stock split and shared news of securing a financial commitment from Canada's government to be used for a Phase 3 clinical study of its EB05 (paridiprubart) therapeutic candidate.
  • Palantir Technologies (NYSE: PLTR): The data and software company saw high volatility during the week, which could be related to the conflict in the Middle East and recent updates from the company. Palantir, which has contracts with multiple government agencies and defense organizations around the world, announced a new contract award from the U.S. Department of Defense worth up to $250 million. Palantir supports the Department of Defense with artificial intelligence and machine learning capabilities. Shares of Palantir are up over 180% year-to-date in 2023.
  • Akero Therapeutics (NASDAQ: AKRO): The biotech company saw shares down sharply on the week after reporting data from a Phase 2b study of its treatment for nonalcoholic steatohepatitis (NASH). The company’s Efruxifermin did not come in ahead of the placebo in improving liver scarring without worsening of NASH. Multiple analysts lowered their price target on the stock. Morgan Stanley, Cantor Fitzgerald, HC Wainwright, JPMorgan Chase & Co. and UBS all kept ratings of Overweight or Buy but lowered price targets from the $60s and $70s to a range of $33 to $41. Shares of Akero trade under $15 at the time of writing, down 70% in the last five days.
  • Tupperware Brands Corp (NASDAQ: TUP): The consumer products company saw increased volatility and trading, which led to a 90% move up for share over the last week. The stock became a trending ticker on several finance sites. An SEC filing from the company also showed amendments made to an existing credit agreement, which extended the deadline to deliver financial statements and a Turnaround Plan. High short interest in the company has also attracted investors with over 20% of the float short.
  • Plug Power Inc (NASDAQ: PLUG): The hydrogen fuel cell company saw increased attention from investors and shares traded higher on the week after the company held its fifth annual Plug Symposium. The company shared updated guidance for long-term revenue with $6 billion now expected in 2027 and $20 billion in 2030. Plug Power could also be seeing increased interest as the Biden administration is expected to award more federal grants related to clean hydrogen fuel.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

  • Sept. 22
  • Sept. 29
  • Oct. 6

Read Next: Generative AI Is As Transformative As The Telephone, Bank Of America Says: 10 Stock, ETF Trading Ideas

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.